Cellyan Biotechnology Co. vs Henry Schein
Henry Schein is the larger business, with $13.18bn of revenue in fiscal 2025 against $13.4m for Cellyan Biotechnology Co. (981.4 times as much). Henry Schein grew faster (4.0% against -33.9%). Henry Schein kept more of each dollar of sales as profit: a net margin of 3.0% against -8.5%. Cellyan Biotechnology Co. carries less debt relative to equity (9.1% against 95.7%).
| Latest fiscal year | Cellyan Biotechnology Co.HKPD, 2026 | Henry ScheinHSIC, 2025 |
|---|---|---|
| Revenue | $13.4m | $13.18bn |
| Revenue growth | -33.9% | 4.0% |
| Net income | −$1.1m | $398m |
| Operating margin | -17.8% | 5.0% |
| Net margin | -8.5% | 3.0% |
| Return on equity | -15.5% | 12.0% |
| Free cash flow | −$787,072 | $573m |
| Cash | $221,841 | $156m |
| Total debt | $877,904 | $3.11bn |
| Debt to equity | 9.1% | 95.7% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $850m |
| Employees | — | 25,000 |
| Market value | $30.1m | $9.21bn |
| Price vs our value range | — | Within our value range |
| Moat score | — | 57 (Moderate) |
| Insider trades, 12 months | 0 buys, 0 sales | 1 buys, 10 sales |